Every 424B that AIM ImmunoTech Inc. (AIM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AIM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIM filings page.
AIM ImmunoTech Inc. registers for resale up to 13,077,089 shares of Common Stock held by selling stockholders, consisting of PIPE Shares, Pre-Funded Warrant Shares, Class J Warrant Shares and June Offering Placement Agent Warrant Shares. The prospectus states the resale is by the selling stockholders and that AIM will not receive proceeds from resale; the company would receive proceeds only if certain warrants are exercised for cash. The filing bases outstanding share counts on 27,724,245 shares outstanding as of June 12, 2026 and shows a pro forma outstanding amount of 40,801,334 shares assuming full exercise of the referenced warrants. The offering arose from a June 10, 2026 registered direct offering and concurrent private placement (the “June Offering”), which included registered shares, PIPE Shares, Pre-Funded Warrants and Class J Warrants.
AIM ImmunoTech Inc. registered for resale up to 31,287,933 shares of Common Stock by the identified Selling Stockholders, consisting of shares issuable upon exercise of Class H and Class I Warrants and placement agent warrants. The prospectus states the company will not receive proceeds from resale by the Selling Stockholders; cash proceeds of approximately $14.5 million would result only if all Warrants and Placement Agent Warrants are exercised for cash. The filing lists 24,328,623 shares outstanding as of May 29, 2026 and discloses post‑exercise outstanding shares would be 55,616,556 assuming full exercise.
AIM ImmunoTech Inc. is offering 2,554,119 registered shares of Common Stock at $0.5189 per share. The prospectus supplement describes a concurrent private placement to accredited investors for 771,503 unregistered shares, pre-funded warrants to purchase 1,782,616 shares and Class J warrants to purchase up to 10,216,476 shares. Net proceeds from the registered offering are estimated at approximately $1.2 million after placement agent fees and estimated offering expenses; proceeds are intended to support a planned Phase 3 trial for Ampligen, manufacture clinical drug supply and for working capital. The Common Warrants become exercisable only upon the Stockholder Approval Date and will expire five years thereafter; the Pre-Funded Warrants are exercisable immediately at $0.001 per share. The offering is on a reasonable best efforts basis with no minimum and is subject to lock-ups, placement agent compensation (cash fees and warrants), and NYSE American continued-listing risks.
AIM ImmunoTech Inc. is offering 7,519,351 shares of Common Stock at $0.325 per share pursuant to a prospectus supplement, with estimated net proceeds of approximately $2.2 million.
In a concurrent private placement (exempt from this prospectus), the company is also offering Series I Common Warrants to purchase up to 15,038,702 shares at an exercise price of $0.325 per share; the warrants become exercisable only upon stockholder approval and expire five years after the Stockholder Approval Date. The offering is being conducted on a reasonable best efforts basis with Ladenburg Thalmann & Co. Inc. acting as sole placement agent.
AIM Immunotech Inc. supplements its prospectus to suspend its at-the-market equity distribution agreement and terminate the continuous offering. The Prospectus had registered the offer and sale of up to $3,409,174 of common stock under an Equity Distribution Agreement with Maxim Group LLC. As of this supplement dated May 19, 2026, the company reports $2,847,151.09 of common stock sold under the EDA and a last reported sale price of $0.4080 per share on May 18, 2026. The supplement states the company will not make any sales under the EDA unless and until a new prospectus supplement is filed; the EDA itself remains in full force and effect.
Amid an existing shelf registration, AIM ImmunoTech, Inc. filed a prospectus supplement dated April 10, 2026 to increase the maximum aggregate offering price under its equity distribution agreement with Maxim Group LLC to $3,409,174. The supplement relies on General Instruction I.B.6 of Form S-3 and notes a public float of $10,227,521 calculated using 8,182,017 shares held by non‑affiliates at $1.25 per share (closing price on February 13, 2026).
The company states it has sold $2,288,758.60 under the instruction during the prior 12 months and is eligible to sell an additional $1,120,415. Sales, if any, may be made as “at the market offerings” through Maxim, which may receive compensation up to 3.0% of gross proceeds. The supplement affirms Maxim will be deemed an underwriter for these sales and that indemnification provisions apply.
AIM ImmunoTech Inc. is offering Subscription Rights to purchase up to 12,000 Units. Each Unit carries one share of Series G Convertible Preferred Stock (convertible at a $1.00 conversion price) and 2,000 Warrants exercisable at $1.00 per share, representing up to 24,000,000 Warrant shares and up to 12,000,000 common shares issuable on conversion.
The Rights Offering has a subscription price of $1,000 per Unit, a Record Date of February 10, 2026, and an expiration date of March 3, 2026. The supplement revises earlier terms by lowering the conversion and exercise prices to $1.00 and increasing the number of Warrants to 24,000,000.
ImmunoTech Inc. is conducting a rights offering of up to 12,000 Units at $1,000 per Unit, for up to $12 million in gross proceeds. Each Unit includes one share of Series G convertible preferred stock plus 1,666 five-year warrants, each warrant exercisable at $1.20 per share.
Each preferred share is convertible into common stock at $1.20 per share, so a fully subscribed offering would add up to 9,996,000 shares from conversions and 19,992,000 shares from warrant exercises. Existing common and specified warrant and option holders receive one non‑transferable subscription right per share as of February 10, 2026, with rights expiring on February 27, 2026.
The company expects net proceeds of about $10.65 million if fully subscribed, before other expenses and excluding any warrant exercise proceeds, and plans to use the cash for general corporate purposes, including clinical trial and manufacturing costs for pancreatic cancer programs, and to repay certain debt.
AIM ImmunoTech Inc. launched an at-the-market offering of up to $2,288,760 of common stock under a new Equity Distribution Agreement with Maxim Group LLC, acting as sales agent. Shares may be sold from time to time on the NYSE American or through other permitted methods, with Maxim earning a 3.0% commission on gross proceeds. The program is conducted under Form S-3 General Instruction I.B.6, which limits sales to one-third of the aggregate market value of non‑affiliate shares.
The company notes non‑affiliate market value of approximately $7,704,936 based on 2,675,325 non‑affiliate shares at $2.88 as of September 25, 2025, leaving $2,288,760 available under the cap. The last reported sale price was $2.62 on October 27, 2025. Shares outstanding were 2,764,188 as of October 27, 2025. On an illustrative basis, the company shows up to approximately 3,637,761 shares outstanding after this offering, assuming 873,573 shares sold at $2.62. Net proceeds, if any, will be used for working capital and general corporate purposes. The filing highlights risks including dilution, price volatility, and broad discretion in use of proceeds.